您的当前位置:首页 > 行业数据 > 全球制药公司历年研发管线数量(数据统计截至2022年1月4日)
图片属性
图片格式:PNG 图片大小:137KB 图片尺寸:1943*919
同报告图片
 / 4
全球制药公司历年研发管线数量(数据统计截至2022年1月4日)_第1页
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
全球制药公司历年研发管线数量(数据统计截至2022年1月4日)_第2页
全球制药公司历年研发管线数量(数据统计截至2022年1月4日)_第3页
fCDlubTku70gfCDmr5vliKnnjocgfCDlh4DliKnnjocgfAp8LS0tLS0tfC0tLS0tLS0tfC0tLS0tLS0tfAp8IDIwMTggfCA0Mi4zOSUgfCAxNC45NiUgfAp8IDIwMTkgfCA0NS44OSUgfCAyMC41MyUgfAp8IDIwMjAgfCA0OS42MSUgfCAyMS4zNSUgfAp8IDIwMjEgfCA1My40MSUgfCAyMi4wNCUgfAp8IDIwMjIgfCA1NS40OCUgfCAyMy4zNiUgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45YWs5ZGK77yM5Lit6YKu6K+B5Yi456CU56m25omA
全球制药公司历年研发管线数量(数据统计截至2022年1月4日)_第4页
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
全球制药公司历年研发管线数量(数据统计截至2022年1月4日)_第5页
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
所属报告: 阳光诺和-公司研究报告-仿创CRO双布局研发转化+权益分成驱动业绩进入加速期-230315(33页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠